Measurement of MMP-14 Protein, a Potential New Marker for Colorectal Cancer Detection, in Plasma Vesicles Named Exosomes

Inclusion criteria

Individuals presenting for colonoscopy with a positive FIT result.

• Positive fecal immunoassay requiring total colonoscopy under general anesthesia.
• Persons having agreed to participate in the study (signed consent form)
• Adults affiliated to a health insurance scheme.

Non-inclusion criteria:

• History of other cancer not in remission or in remission for less than five years (with the exception of cervical cancer or basal cell skin cancer treated with curative intent)
• Patients undergoing chemotherapy
• Patients protected by law This is a cross-sectional multicenter interventional study. Patients will be recruited from the Hepato-Gastroenterology departments of the CHU de Reims, CHU de Dijon, CHU de Nancy, CHU de Besançon, CH de Châlons-en-Champagne, Institut Jean Godinot de Reims, CHU de Strasbourg, CH de Charleville Mézières and CH d'Epernay.

Once consent has been signed and the patient has been included in the study, blood will be drawn from 2 additional tubes of 5 ml each, either in the consultation room or in the operating room, when the infusion is set up for colonoscopy under general anaesthetic. Plasma will be collected at the various participating facilities (2 x 5mL EDTA tubes), centrifuged at 1000g for 10 minutes, then frozen at -80°C. Samples will then be sent to the Reims University Hospital Biology Department for storage before analysis.

The isolation of exosomes from the patient's plasma and their characterization: size, number (determined using the Malvern Panalytical NanoSight NS300), and MMP14 concentration (determined by enzyme-linked immunosorbent assay), will be carried out at the CNRS UMR7369 "Matrice Extracellulaire et Dynamique Cellulaire (MEDyC)" unit at the University of Reims Champagne Ardenne.

Inclusion criteria

• Individuals presenting for colonoscopy with a positive FIT result.
• Positive fecal immunoassay requiring total colonoscopy under general anesthesia.
• Persons having agreed to participate in the study (signed consent form)
• Adults affiliated to a health insurance scheme.

Exclusion criteria

• History of other cancer not in remission or in remission for less than five years (with the exception of cervical cancer or basal cell skin cancer treated with curative intent)
• Patients undergoing chemotherapy
• Legally protected individuals